New Studies Showcase Benefits of Blue Light Cystoscopy in High-Risk NMIBC Management

At the AUA 2026, Photocure ASA presented two abstracts highlighting the advantages of Blue Light Cystoscopy (BLC) in managing high-risk non-muscle-invasive bladder cancer (NMIBC). The first study established that BLC improves early detection of carcinoma in situ (CIS), guiding better clinical decisions for patients. The second study conducted a cost comparison between BLC and white light cystoscopy (WLC), indicating that despite higher initial costs, BLC’s lower recurrence rates lead to overall cost neutrality, thus providing a compelling case for its broader adoption in clinical practice.